ADPT Stock Recent News
ADPT LATEST HEADLINES
Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Adaptive Biotechnologies and Netflix were top contributors, driven by strong earnings, momentum in core businesses, and positive outlooks. UnitedHealth Group and Visa detracted from performance due to earnings weakness, guidance cuts, and potential disruption from stablecoins. We initiated a position in HubSpot for its strong SMB positioning, AI-driven growth, and scalable financials, while exiting Expedia due to recession risks.
Just after market close, Adaptive Biotechnologies (ADPT 5.97%) took the wraps off its second quarter. The following day, investors reacted to this by bidding the biotech company's stock up by almost 6%.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Chad M. Robins - Co-Founder, CEO & Chairman Karina Calzadilla - Vice President of Investor Relations Kyle Piskel - VP, CFO & Principal Accounting Officer Susan Bobulsky - Chief Commercial Officer of MRD Conference Call Participants Andrew Frederick Brackmann - William Blair & Company L.L.C.
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.26 per share a year ago.